PerspectiveType 2 Diabetes

α2A-Adrenergic Receptors in the Genetics, Pathogenesis, and Treatment of Type 2 Diabetes

See allHide authors and affiliations

Science Translational Medicine  23 Dec 2009:
Vol. 1, Issue 12, pp. 12ps15
DOI: 10.1126/scitranslmed.3000606

You are currently viewing the abstract.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution


Insulin secretion from pancreatic islets is inhibited by the activation of β cell α2A-adrenergic receptors (α2AARs). Increased expression of α2AARs, then, would depress insulin release, which is a pathogenic mechanism of type 2 diabetes. Using congenic rats derived from an inbred model of type 2 diabetes, Rosengren et al. showed that a chromosomal region that includes the gene encoding α2AAR, Adra2a, is associated with increased messenger RNA and protein expression and decreased insulin release. A single-nucleotide polymorphism in the human ADRA2A gene was associated with decreased insulin secretion in normal people during glucose challenge and was also associated with type 2 diabetes. These findings offer another genetic association locus for the disease, with concordant biochemical and expression phenotypes, and also provide a potential new pathway for therapeutic intervention.


  • Citation: S. B. Liggett, α2A-Adrenergic receptors in the genetics, pathogenesis, and treatment of type 2 diabetes. Sci. Transl. Med. 1, 12ps15 (2009).

View Full Text

Stay Connected to Science Translational Medicine